OXIS INTERNATIONAL, INC. – Trademark Portfolio

Entity Type: 03

OXIS INTERNATIONAL, INC. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. The owner is based in PORTLAND, OR.

6040 N. CUTTER CIRCLE

SUITE 317

PORTLAND, OR 972173935

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

REVERGE
REVERGE
Cancelled 2012
PROGRACE
PROGRACE
Cancelled 2012
ERGOLD
ERGOLD
Abandoned 2003
PROCLAIM
PROCLAIM
Abandoned 1995
AFFIRM
AFFIRM
Abandoned 1995
PALOSEIN
PALOSEIN
Cancelled 1970

Trademark Classifications

OXIS INTERNATIONAL, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (4 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (2 filings)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does OXIS INTERNATIONAL, INC. have?

OXIS INTERNATIONAL, INC. has 7 U.S. trademarks filed with the USPTO.

What trademark classes does OXIS INTERNATIONAL, INC. file in?

OXIS INTERNATIONAL, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is OXIS INTERNATIONAL, INC.'s trademark registration success rate?

OXIS INTERNATIONAL, INC. has a 0% trademark registration rate, with 0 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.